secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001104659-24-088956
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis Q2 net loss $56.5M, cash $209.5M; Phase 3 psoriasis trial initiated
--------------------------------------------------------------------------

- Net loss $56.5M for Q2 2024 vs $36.3M in Q2 2023; R&D expense $48.6M (up from $32.8M).
- Cash and marketable securities $209.5M at June 30; IPO net proceeds $233.2M extend runway into 2026.
- Initiated ESK-001 Phase 3 ONWARD program in moderate-to-severe plaque psoriasis; topline expected 2026.
- Completed IPO and concurrent private placement raising $250M gross proceeds (15.625M shares at $16.00).
- Phase 1 trial for A-005 (CNS-penetrant TYK2 inhibitor) dosed first healthy volunteer in April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465924088956/0001104659-24-088956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465924088956/tm2421483d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer